Cancer treatment and research communications最新文献

{"title":"Breast cancers with neuroendocrine differentiation: Retrospective case studies series from a single institution based on the 2019 WHO classification","authors":"Youngkyung Jeon ,&nbsp;Ji-Yeon Kim ,&nbsp;Jin Seok Ahn ,&nbsp;Young-Hyuck Im ,&nbsp;Kyuehee Choi ,&nbsp;Sun Young Jeong ,&nbsp;Yeji Jung ,&nbsp;Jaeyeon Jang ,&nbsp;Dae-Ho Choi ,&nbsp;Joohyun Hong ,&nbsp;Hyo Jung Kim ,&nbsp;Soo Youn Cho ,&nbsp;Yeon Hee Park","doi":"10.1016/j.ctarc.2024.100857","DOIUrl":"10.1016/j.ctarc.2024.100857","url":null,"abstract":"<div><h3>Background</h3><div>The World Health Organization's fifth edition of tumor series classification was published in 2019 and adopted the term ‘Neuroendocrine neoplasm (NEN)’ to encompass all tumor classes with predominant neuroendocrine differentiation (NED). Based on the updated classification of the NEN, we conducted a case series using the Clinical Data Warehouse platform of SMC.</div></div><div><h3>Methods</h3><div>In this retrospective study, breast NENs and invasive breast carcinomas no special type (IBC<img>NST) with NED, were defined as 'NENS’. Based on pathology slide findings, a pathologist reclassified the diagnoses. Clinical presentation, tumor characteristics, and clinical outcomes of breast ‘NENS’ were reviewed retrospectively.</div></div><div><h3>Results</h3><div>A total of 34,370 patients were diagnosed with breast cancer from 1995 to 2022 in SMC, and 14 (0.04 %) patients were diagnosed with breast ‘NENS’: eight NECs, three NETs, and three IBC<img>NST with NED. The patients’ median age was 48.5 years. All patients were treated with curative intent surgery; five patients received neoadjuvant chemotherapy, twelve patients received radiotherapy, six patients received adjuvant chemotherapy, and eight patients received hormone therapy. The median follow-up period for the eight patients with breast NEC was 20.4 months. The median disease-free and overall survival were 14.2 months and 23.6 months, respectively. Patients with NET or IBC<img>NST with NED (<em>n =</em> 6) had an overall favorable outcome, with no deaths, with only one case of disease recurrence.</div></div><div><h3>Conclusion</h3><div>The incidence of primary breast NENS’ was very low (0.04 %) in this single-center study. Among them, primary breast NEC was associated with poor overall survival. Novel treatments are thus required to improve the prognosis of primary breast NEC.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100857"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142884971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WGCNA and integrative network analysis identify CHRNA5 and CTLA4 as potential therapeutic targets against angiosarcoma","authors":"Trishla Bhatnagar ,&nbsp;Madiha Haider ,&nbsp;Mohd Yasir Khan ,&nbsp;Mohammad Zahid Ashraf","doi":"10.1016/j.ctarc.2024.100862","DOIUrl":"10.1016/j.ctarc.2024.100862","url":null,"abstract":"<div><div>Angiosarcomas are a type of soft-tissue sarcoma characterized by aggressive malignant tumors originating from endothelial cells of blood vessels or lymphatic vessels. Limited studies have been done to explore the molecular pathophysiology of the disease, with rather limited studies involving transcriptomic analyzes. This study was undertaken to identify the shared molecular signatures and gene modules associated with angiosarcomas of various origin. Transcriptomic data analysis of publicly available data was done followed by WGCNA to identify shared signature gene modules. The Maximal Clique Centrality algorithm was applied to gene modules, and unclustered network analysis was conducted on differentially expressed genes to identify true hub genes. The expression of candidate genes in various cancer types was analyzed using GEPIA. WGCNA analysis identified five significant modules, with the most enriched module being associated with angiogenesis and cell junction regulators. The intersection of true hub genes from MCC analysis of WGCNA modules and high-degree nodes from an unclustered network revealed eight consistently overexpressed genes in all angiosarcoma samples.Among the eight enriched genes, CHRNA5 and CTLA4, are exclusively overexpressed in angiosarcoma and not in other cancers of the same tissue origin, with significant drug-protein interactions suggesting their potential as therapeutic targets.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100862"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Evaluating Current Diagnostic and Treatment Challenges in Colorectal Cancer: Strategies for improving care and outcomes in Georgia\"","authors":"Saba Kopadze ,&nbsp;Ivane Kiladze","doi":"10.1016/j.ctarc.2025.100866","DOIUrl":"10.1016/j.ctarc.2025.100866","url":null,"abstract":"<div><h3>Purpose</h3><div>An initial analysis of population-based cancer survival data from Georgia revealed lower CRC survival rates compared to high-income countries. We conducted the study to address this issue and propose strategies for enhancing CRC care.</div></div><div><h3>Patients and Methods</h3><div>We analyzed CRC statistics, reviewed screening programs, and examined published CRC research in Georgia. Finally, we surveyed 16 oncologists from major institutions all over the country to assess molecular testing, treatment standards, and access to modern medications.</div></div><div><h3>Results</h3><div>Despite CRC screening being available in Georgia, late diagnoses persist, with over a 1/3 of cases presenting with acute intestinal obstruction. As a result, 65 % of CRC patients are diagnosed at locally advanced or metastatic stages. All 16 oncologists reported limited molecular testing due to costs, with 13 not routinely performing MSI/MMR and NRAS/KRAS/BRAF testing. Consequently, only 15 % of patients receive anti-EGFR therapy. Oxaliplatin-based therapy is almost universally used for metastatic CRC as the first-line treatment. No CRC clinical trials have been conducted in Georgia over the past three years. Treatment for locally advanced rectalcancer typically includes chemoradiotherapy followed by surgery, with notable variation in multidisciplinary team meeting practices.</div></div><div><h3>Conclusions</h3><div>Study provides several practical recommendations: it is crucial to promote CRC screening programs, enhance access to modern treatment options, and standardize national diagnostic/treatment protocols. There is an urgent need for more clinical trials to increase access to modern therapeutics, as well as to strengthen MDT meetings. These measures are expected to improve CRC care with a further reduction in CRC mortality rates.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100866"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge and practice of health promotive lifestyle toward cervical cancer prevention among women in Africa: A scoping review","authors":"Mary Opeyemi Adigun ,&nbsp;Deborah Tolulope Esan ,&nbsp;Babatunji Emmanuel Oyinloye ,&nbsp;Benedict Tolulope Adeyanju ,&nbsp;Kikelomo Sabainah Olowoyo ,&nbsp;David Bamidele Olawade","doi":"10.1016/j.ctarc.2025.100877","DOIUrl":"10.1016/j.ctarc.2025.100877","url":null,"abstract":"<div><h3>Introduction</h3><div>Cervical cancer remains a significant public health concern among women globally, with a high burden of morbidity and mortality. Despite the existence of empirical evidence about various preventive strategies, the burden of cancer continues to rise, particularly in developing countries like Nigeria. This scoping review aimed to examine the existing literature on the knowledge and practice of health-promotive lifestyle factors for the prevention of cervical cancer among women in Nigeria. This review is driven by the acknowledgment that early detection and prevention are crucial in mitigating the impact of cervical cancer.</div></div><div><h3>Method</h3><div>A systemic search of databases; PubMed, Embase, Google Scholar, Medline, Semantic Scholars was also conducted to identify relevant studies published between 2019 and 2023. Relevant articles were screened for eligibility, and 46 papers were selected. The Joanna Briggs Institute and Preferred Reporting Items for Systematic Review and Meta-analysis Scoping Review Extension (PRISMA-ScR) guidelines were used to analyze the quality of the articles.</div></div><div><h3>Results</h3><div>The study affirmed that various studies have been done concerning knowledge and practice of cervical cancer prevention among women in Africa. The knowledge, attitude and practice of cervical cancer prevention was poor among these women, which has had a direct influence in the poor uptake of cervical cancer screening among Africa women. However, nurse led interventions has been proven to increase knowledge level and screening uptake in experimental groups post intervention.</div></div><div><h3>Conclusions</h3><div>While some women have good knowledge of cervical prevention, the attitude and practice of prevention is poor in many of the studies reviewed. The uptake of screening was low, and some barriers identified encompasses socio-cultural concerns, cost, insufficient health education, limited availability of healthcare services, and consent from partners, while family history of cervical cancer is one of the reasons for uptake of screening in some women.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100877"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143387329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The real-world insights on the use, safety, and outcome of immune-checkpoint inhibitors in underrepresented populations with lung cancer","authors":"Xiao Hu ,&nbsp;Jeffrey H. Lin ,&nbsp;Stacey Pan ,&nbsp;Yana V. Salei ,&nbsp;Susan K. Parsons","doi":"10.1016/j.ctarc.2024.100833","DOIUrl":"10.1016/j.ctarc.2024.100833","url":null,"abstract":"<div><h3>Background</h3><p>The data on immune checkpoint inhibitors (ICI) use in lung cancer individuals generally underrepresented in clinical trials are limited. We aimed to examine the ICI access, safety, and outcome in these populations using real-world data.</p></div><div><h3>Methods</h3><p>Patients with lung cancer newly started on ICIs from 2018 to 2021 were included. Patient factors (age, sex, race, insurance, Charlson comorbidity index (CCI), Eastern Cooperative Oncology Group (ECOG) performance status, histories of autoimmune disease (AD), infection within 3 months before treatment, and brain metastasis) were collected and grouped. Associations of each patient factor with the time-to-treatment initiation (TTI) of ICIs and immune-related adverse events (irAEs) were examined via cumulative incidence analyses and Chi-squared tests, respectively. Log-rank tests and Cox models were used to assess association of patient factors with overall survival (OS).</p></div><div><h3>Results</h3><p>Of 125 patients (median age:70 years (50–88), 68 (54.4 %) males), 9 (7.2 %) had Medicaid/uninsured, 44 (35.2 %) had ECOG ≥ 2, 101 (80.8 %) had CCI ≥ 3, 16 (12.8 %) had ADs, 14 (11.2 %) had infections, and 26 (20.8 %) had brain metastases. In newly diagnosed stage IV patients (<em>N</em> = 62), no difference in TTI was found by patient factors. Fifty irAEs occurred within 12 months and no differences in irAEs occurrence by patient factors. In advanced-stage group (<em>N</em> = 123), OS did not differ by patient factors, except for race (<em>p</em> = 0.045). Whites showed an inferior OS than non-Whites in multivariable regression. (Hazards ratio = 2.82 [1.01–7.87], <em>p</em> = 0.047).</p></div><div><h3>Conclusions</h3><p>Previously poorly represented subgroups were shown to have no significant delays in ICI use, general tolerance, and comparable outcomes. This adds practical evidence to ICI use in clinically and/or socio-demographically marginalized populations.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100833"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000455/pdfft?md5=d6e48f89684fa10847abbc2cc41ad10b&pid=1-s2.0-S2468294224000455-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141622993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study","authors":"Yuichiro Nishibori ,&nbsp;Hirotsugu Kenmotsu ,&nbsp;Kenju Ando ,&nbsp;Ayumi Tonsho ,&nbsp;Suguru Matsuda ,&nbsp;Meiko Morita ,&nbsp;Motoki Sekikawa ,&nbsp;Kosei Doshita ,&nbsp;Noboru Morikawa ,&nbsp;Keita Miura ,&nbsp;Hiroaki Kodama ,&nbsp;Michitoshi Yabe ,&nbsp;Yuko Iida ,&nbsp;Nobuaki Mamesaya ,&nbsp;Haruki Kobayashi ,&nbsp;Ryo Ko ,&nbsp;Kazushige Wakuda ,&nbsp;Akira Ono ,&nbsp;Tateaki Naito ,&nbsp;Haruyasu Murakami ,&nbsp;Toshiaki Takahashi","doi":"10.1016/j.ctarc.2024.100849","DOIUrl":"10.1016/j.ctarc.2024.100849","url":null,"abstract":"<div><h3>Objectives</h3><div>The current standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiation therapy (CCRT) followed by durvalumab consolidation therapy. Although the trial revealed the survival benefit of adding an immune checkpoint inhibitor (ICI) to the population, the optimal treatment strategy and efficacy of subsequent treatment after relapse remain unclear.</div></div><div><h3>Materials and methods</h3><div>We retrospectively collected data from patients with unresectable LA-NSCLC who completed platinum-based CCRT as first-line treatment. Patients who received molecular-targeted therapy for driver gene alterations or did not receive durvalumab as consolidation therapy following the approval were excluded. We assessed differences in regimen and efficacy of subsequent treatment in patients who underwent durvalumab consolidation therapy (D group) and those who did not (CR group).</div></div><div><h3>Results</h3><div>Among the 62 eligible patients, 32 were assigned to the D group and 30 to the CR group. Patients in the CR group were more frequently treated with an immune checkpoint inhibitor (ICI)-containing regimen than those in the D group (57 % vs. 13 %, <em>p</em> &lt; 0.001). The median overall survival from initiation of subsequent treatment was shorter in the D group than in the CR group (13.0 months vs. 26.7 months, hazard ratio 2.60; 95 % confidence interval: 1.28–2.56, <em>p</em> = 0.008).</div></div><div><h3>Conclusions</h3><div>Patients with unresectable LA-NSCLC who relapsed after durvalumab consolidation therapy received an ICI-containing regimen less frequently, and the efficacy of the subsequent treatment was limited.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"41 ","pages":"Article 100849"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the role of MSH2 and MSH6 gene expression deficiency in prostate cancer progression, a cross-sectional study","authors":"Fatemeh Sharbati,&nbsp;Hedieh Moradi Tabriz,&nbsp;Elham Nazar","doi":"10.1016/j.ctarc.2024.100826","DOIUrl":"10.1016/j.ctarc.2024.100826","url":null,"abstract":"<div><h3>Background</h3><p>Recently, some evidence emphasized the value of MSH2 and MSH6 inactivation and their hypermutation in predicting different cancers. The present consideration is to evaluate the value of MSH2 and MSH6 protein deficient studied by the immunohistochemistry (IHC) method and the tumor behaviors and aggressiveness in prostatic carcinoma.</p></div><div><h3>Methods</h3><p>This cross-sectional study was performed on 80 examples extricated from patients who endured prostate cancer and were planned for radical prostatectomy surgery. The expression levels of the genes were studied by IHC staining.</p></div><div><h3>Results</h3><p>The deficiency in MSH2 and MSH6 expression was revealed in 10.0 % and 11.3 % of patients respectively, while the reduction of simultaneous expression in two genes was found in 6.2 % of patients. In the two subgroups with and without MSH2 and/or MSH6 staining, there was no difference in patients' mean age and history of prostate cancer. There was also no difference in tumor-related behaviors including combined Gleason grade group, tumor stage, vascular invasion, perineural invasion, and prostatic capsular invasion between the groups with and without gene loss.</p></div><div><h3>Conclusion</h3><p>The evaluation of the deficient rate of two genes among patients with prostate cancer to predict the tumor grade and its aggressive behavior needs further study in every population.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100826"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000388/pdfft?md5=fed1219763129e48f95540243616817c&pid=1-s2.0-S2468294224000388-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate cancer knowledge and barriers to screening among men at risk in northern Tanzania: A community-based study","authors":"Bartholomeo Nicholaus Ngowi ,&nbsp;Alex Mremi ,&nbsp;Orgeness Jasper Mbwambo ,&nbsp;Modesta Paschal Mitao ,&nbsp;Mramba Nyindo ,&nbsp;Kien Alfred Mteta ,&nbsp;Blandina Theophil Mmbaga","doi":"10.1016/j.ctarc.2024.100811","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100811","url":null,"abstract":"<div><h3>Background</h3><p>Although prostate cancer (Pca) screening plays important role in early diagnosis and reduction of mortality, Tanzanian men are relatively unscreened. We aimed to investigate Pca knowledge level and barriers to screening among at-risk men in northern Tanzania.</p></div><div><h3>Methods</h3><p>This community-based survey was conducted in northern Tanzania from May to September 2022, involving men age ≥40 years. Participants were invited by announcing in local churches, mosques, brochures, and social media groups. Participants attended a nearby health facility where survey questionnaires were administered. Knowledge level was measured on the Likert scale and scored as poor (&lt;50 %) or good (≥50 %).</p></div><div><h3>Results</h3><p>A total of 6205 men with a mean age of 60.23 ± 10.98 years were enrolled in the study. Of these, 586 (9.5 %) had ever been screened for Pca. Overall, 1263 men (20.4 %) had good knowledge of Pca. Having health insurance, knowing at least 1 risk factor or symptoms of Pca, and hospital as the source of Pca information were significantly associated with ever being screened. The most common reasons for not being screened were a belief that they are healthy (<em>n</em> = 2983; 53.1 %), that Pca is not a serious disease (<em>n</em> = 3908; 69.6 %), and that digital rectal examination (DRE) as an embarrassing (<em>n</em> = 3634; 64.7 %) or harmful (<em>n</em> = 3047; 54.3 %) procedure.</p></div><div><h3>Conclusion</h3><p>Having Pca knowledge, health insurance and hospital source of information were correlated with increased screening. False beliefs about DRE and the seriousness of Pca had negative effects on screening. Increasing community knowledge and universal health coverage would improve uptake of Pca screening.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100811"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000236/pdfft?md5=278085955eb28f5b88051eb990ce9c00&pid=1-s2.0-S2468294224000236-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140341213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial","authors":"Dilyara Kaidarova ,&nbsp;Edvard Zhavrid ,&nbsp;Oxana Shatkovskaya ,&nbsp;Aliaksandr Prokharau ,&nbsp;Nina Akhmed ,&nbsp;Dauren Sembayev ,&nbsp;Zhanna Rutzhanova ,&nbsp;Alexandr Ivankov","doi":"10.1016/j.ctarc.2024.100817","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100817","url":null,"abstract":"<div><h3>Aim</h3><p>To assess the safety and tolerability of subcutaneous (SC) trastuzumab (Herceptin) administered either with a single-use injection device (SID) or manually from a vial using a hand-held syringe.</p></div><div><h3>Methods</h3><p>The ESCAPE trial (NCT02194166) included 90 women aged 18 years or older with HER2-positive early breast cancer who underwent surgical treatment and completed (neo) adjuvant chemotherapy and radiotherapy (if indicated). Patients enrolled in the study were first subjected to 4 cycles of trastuzumab IV (8 mg/kg loading dose followed by 6 mg/kg maintenance dose, q3w) prior to being randomized into groups: [A] SC trastuzumab (fixed dose 600 mg, q3w) administered through a hand-held syringe followed by 7 cycles of SC trastuzumab administered with an SID or [B] the reverse sequence.</p></div><div><h3>Results</h3><p>Patient-reported outcomes revealed that 78 (94.0 % [95 % CI: 90.4–99.0]) out of 83 patients preferred SC trastuzumab over IV trastuzumab, among whom 28 patients indicated a strong preference. Sixteen out of 17 HCPs (94.1 %) were very satisfied with the use of SC trastuzumab, while 1/17 (5.9 %) remained uncertain. The mean time spent for IV vs. SC trastuzumab administration, including pre- and postinjection procedures, was 93.8 and 22 min, respectively. A total of 49 (54.4 %) patients reported 164 AEs.</p></div><div><h3>Conclusions</h3><p>In this trial, SC trastuzumab was preferred over IV trastuzumab. The duration of SC trastuzumab administration was significantly shorter than that of IV trastuzumab, saving patients and HCPs time. Safety and efficacy results were consistent with other published trials and were not associated with any new safety signal.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100817"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000297/pdfft?md5=082e01b0512576154bebb1218d234e96&pid=1-s2.0-S2468294224000297-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140909796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach","authors":"Lærke Rosenlund Nielsen ,&nbsp;Simone Stensgaard ,&nbsp;Peter Meldgaard ,&nbsp;Boe Sandahl Sorensen","doi":"10.1016/j.ctarc.2024.100802","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100802","url":null,"abstract":"<div><h3>Background</h3><p>Reliable biomarkers are needed to identify tumor recurrence of non-small cell lung cancer (NSCLC) patients after chemoradiotherapy (CRT) with curative intent. This could improve consolidation therapy of progressing patients. However, the approach of existing studies has limited transferability to the clinic.</p></div><div><h3>Materials and methods</h3><p>A retrospective analysis of 135 plasma samples from 56 inoperable NSCLC patients who received CRT with curative intent was performed. Plasma samples collected at baseline, at the first check-up (average 1.6 months post-RT), and at the second check-up (average 4.5 months post-RT) were analyzed by deep sequencing with a commercially available cancer personalized profiling strategy (CAPP-Seq) using a tumor-agnostic approach.</p></div><div><h3>Results</h3><p>Detection of circulating tumor DNA (ctDNA) at 4.5 months after therapy was significantly associated with higher odds of tumor recurrence (OR: 5.4 (CI: 1.1–31), Fisher's exact test: <em>p</em>-value = 0.022), and shorter recurrence-free survival (RFS) (HR: 4.1 (CI: 1.7–10); log-rank test: <em>p</em>-value = 9e-04). In contrast, detection of ctDNA at 1.6 months after therapy was not associated with higher odds of tumor recurrence (OR: 2.7 (CI: 0.67–12), Fisher's exact test: <em>p</em>-value = 0.13) or shorter RFS (HR: 1.5 (CI: 0.67–3.3); log-rank test: <em>p</em>-value = 0.32).</p></div><div><h3>Conclusion</h3><p>This study demonstrates that the detection of ctDNA can be used to identify minimal residual disease 4.5 months after CRT in NSCLC patients using a commercially available kit and a tumor-agnostic approach. Furthermore, the time point of collecting the plasma sample after CRT has decisive importance for the prognostic value of ctDNA.</p></div><div><h3>Micro abstract</h3><p>This study analysed 135 plasma samples from 56 NSCLC patients treated with curative intent chemoradiotherapy using a tumor-agnostic approach. Detecting ctDNA at 4.5 months post-treatment was linked to higher recurrence odds, indicating ctDNA's potential as a biomarker for identifying residual disease after treatment with curative intent. Importantly, the study emphasizes the importance of timing for accurate ctDNA analysis results.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100802"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000145/pdfft?md5=47b4ed51e233a53acd993e7bdb48e2c2&pid=1-s2.0-S2468294224000145-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139999323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}